Tissue Inhibitor of Metalloproteinase 3 Deficiency Disrupts the Hepatocyte E‐Cadherin/β‐Catenin Complex and Induces Cell Death in Liver Ischemia/Reperfusion Injury

Takehiro Fujii, Sergio Duarte, Eudora Lee, Bibo Ke, Ronald W. Busuttil, Ana J. Coito – 22 October 2019 – Tissue inhibitor of metalloproteinase (TIMP) 3 is a naturally occurring inhibitor of a broad range of proteases, with key roles in extracellular matrix turnover and in the pathogenesis of various diseases. In this study, we investigated the response of mice lacking TIMP3 (TIMP3−/−) to hepatic ischemia/reperfusion injury (IRI).

Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years

Faouzi Saliba, Christophe Duvoux, Sébastien Dharancy, Jérôme Dumortier, Yvon Calmus, Jean Gugenheim, Nassim Kamar, Ephrem Salamé, Martine Neau‐Cransac, Claire Vanlemmens, François Durand, Georges Pageaux, Vincent Leroy, Jean Hardwigsen, Hakam Gharbi, Cécile Masson, Malka Tindel, Filomena Conti – 21 October 2019 – The observational CERTITUDE study follows liver transplant patients who completed the SIMCER trial.

Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers

Felix Stickel, Philipp Lutz, Stephan Buch, Hans Dieter Nischalke, Ines Silva, Vanessa Rausch, Janett Fischer, Karl Heinz Weiss, Daniel Gotthardt, Jonas Rosendahl, Astrid Marot, Mona Elamly, Marcin Krawczyk, Markus Casper, Frank Lammert, Thomas W. M. Buckley, Andrew McQuillin, Ulrich Spengler, Florian Eyer, Arndt Vogel, Silke Marhenke, Johann Felden, Henning Wege, Rohini Sharma, Stephen Atkinson, Andre Franke, Sophie Nehring, Vincent Moser, Clemens Schafmayer, Laurent Spahr, Carolin Lackner, Rudolf E. Stauber, Ali Canbay, Alexander Link, Luca Valenti, Jane I. Grove, Guruprasad P.

LiverLearning®: 2019 Webinar: The Diverse Presentation and Diagnosis of Liver Injury Due to Drugs or Herbal and Dietary Supplements

This webinar is targeted to AASLD Associate and Trainee members, as well as Junior Faculty. The goal is to provide an approach to the accurate diagnosis of Drug Induced Liver Injury (DILI), with special attention to considerations that may mask the diagnosis. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Paul (Skip) Hayashi Dr. Hayashi is currently Co-Chair of the Causality Committee for the Drug-Induced Liver Injury Network (DILIN) and Associate Professor at the University of North Carolina (UNC), Chapel Hill, NC.

Subscribe to